Antimicrobial Susceptibility Testing Market By Product Type (Automated Systems, Manual Systems, Consumables), By Test Type (Disk Diffusion, Broth Microdilution, Agar Dilution, E-test), By Technology (Molecular Diagnostics, Phenotypic Methods, Genotypic Methods), By Application (Clinical Diagnostics, Research and Development, Food & Beverage Industry, Veterinary Applications), By End-User (Hospitals and Diagnostic Laboratories, Pharmaceutical and Biotechnology Companies, Research Institutions), By Region ; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Antimicrobial Susceptibility Testing Market was valued at USD 3.3 billion in 2023 and will surpass USD 4.8 billion by 2030; growing at a CAGR of 5.4% during 2024 - 2030.

The antimicrobial susceptibility testing (AST) market is witnessing significant growth, driven by the increasing prevalence of antimicrobial resistance (AMR) and the need for rapid, accurate diagnostic tools. Among the various product types in this market, automated systems dominate due to their efficiency, high-throughput capabilities, and the ability to deliver consistent, accurate results. These systems have become essential in clinical and research laboratories, where they streamline the testing process and allow for rapid identification of resistant pathogens, ensuring timely treatment.

Automated Systems Is Largest Owing to Efficiency and Accuracy

Automated systems in AST are particularly advantageous for large-scale testing environments, such as hospitals and diagnostic labs, where precision and speed are paramount. These systems reduce human error, increase throughput, and provide results faster than manual methods. The adoption of automated systems is further boosted by advancements in technology, including integration with molecular diagnostics and artificial intelligence to enhance the accuracy and interpretability of results. As healthcare facilities strive to improve patient outcomes and combat AMR, automated AST systems remain a critical investment.

Broth Microdilution Is Fastest Growing Due to Precision and Adaptability

The test type segment of the AST market is rapidly expanding, with Broth Microdilution emerging as the fastest-growing subsegment. This method offers greater precision in determining the minimum inhibitory concentration (MIC) of antimicrobial agents, making it a preferred choice for clinical microbiology labs. Its adaptability to various pathogens and antimicrobials has led to its widespread adoption, particularly in research and drug development. The ability to test a broader range of antimicrobial agents in a single assay is driving the growth of Broth Microdilution.

Broth Microdilution is gaining traction due to its ability to provide detailed, reliable data on microbial resistance patterns, which is crucial in the development of new antimicrobial agents. Additionally, this method’s ability to be automated enhances its appeal in clinical settings, where the need for rapid and accurate results is increasing. As the global fight against AMR intensifies, Broth Microdilution’s role in the precise detection of resistance is expected to continue to grow, making it a cornerstone of modern AST methodologies.

Molecular Diagnostics Leads with Innovation in Resistance Detection

Molecular diagnostics is the leading technology in the antimicrobial susceptibility testing market due to its ability to offer rapid, highly accurate results. This technology allows for the identification of resistant pathogens at the genetic level, facilitating early detection of AMR. The ability to detect specific resistance genes, such as those responsible for carbapenem resistance, makes molecular diagnostics invaluable in combating the rise of resistant infections. The need for precise and timely information in clinical settings has led to widespread adoption of molecular diagnostic tools, making them a key driver of market growth.

As the demand for personalized medicine and precision healthcare increases, molecular diagnostics is expected to play a pivotal role in the future of antimicrobial susceptibility testing. The technology’s ability to provide results in hours rather than days significantly improves patient outcomes by enabling healthcare providers to make informed decisions quickly. With advancements in next-generation sequencing (NGS) and PCR-based methods, molecular diagnostics is poised to remain at the forefront of AST, driving innovation and adoption across the healthcare and research sectors.

Clinical Diagnostics Is Largest Due to Rising AMR

The clinical diagnostics application segment dominates the antimicrobial susceptibility testing market, driven by the growing global burden of infectious diseases and antimicrobial resistance. With infections caused by resistant pathogens becoming more common, clinical laboratories are increasingly turning to AST to guide therapeutic decisions. This segment is crucial in ensuring effective treatment regimens and preventing the spread of resistant bacteria in healthcare settings, which has led to sustained demand for AST solutions in clinical diagnostics.

The importance of AST in clinical diagnostics is underscored by its role in antibiotic stewardship programs, which aim to optimize the use of antibiotics in order to slow the development of AMR. These programs are being adopted worldwide, further increasing the demand for accurate and timely AST solutions. As the healthcare industry focuses on improving infection control and treatment protocols, clinical diagnostics remains the largest application segment, expected to continue growing as AMR becomes an even greater global health threat.

Hospitals and Diagnostic Laboratories Lead Market Demand

Hospitals and diagnostic laboratories represent the largest end-user segment in the antimicrobial susceptibility testing market. These institutions require AST solutions to detect and manage infections caused by resistant bacteria, making them key players in the market. The need for accurate diagnostics in hospital settings is essential to prevent the spread of infections, improve patient outcomes, and minimize healthcare costs associated with resistant infections.

North America Is Largest Region Due to Healthcare Infrastructure

North America is the largest regional market for antimicrobial susceptibility testing, owing to its advanced healthcare infrastructure, high adoption of innovative diagnostic technologies, and increasing prevalence of antimicrobial resistance. The U.S., in particular, is home to numerous leading AST manufacturers and research institutions, driving the growth of the market in the region. With well-established healthcare systems and a growing focus on precision medicine, North America is well-positioned to lead the market for AST solutions.

The demand for rapid and accurate antimicrobial susceptibility testing is also supported by robust government initiatives focused on combating AMR, such as the U.S. Centers for Disease Control and Prevention’s (CDC) efforts to improve infection control in hospitals. Moreover, the increasing emphasis on antimicrobial stewardship programs in both the public and private healthcare sectors is expected to further fuel the growth of AST in North America. As a result, this region is set to maintain its position as the largest market for AST, with significant investments in technological advancements and infrastructure.

Competitive Landscape: Leading Companies Drive Market Innovation

The antimicrobial susceptibility testing market is highly competitive, with several global companies leading the charge in innovation and market share. Key players include BioMerieux, Thermo Fisher Scientific, Abbott Laboratories, and Becton Dickinson, among others. These companies dominate the market by offering a wide range of AST solutions, from automated systems and consumables to cutting-edge molecular diagnostics. Their strong market presence is supported by continuous investments in research and development to address the growing challenge of antimicrobial resistance.

In addition to product innovation, partnerships, mergers, and acquisitions (M&A) are also shaping the competitive landscape. For instance, major companies are increasingly collaborating with healthcare providers and research institutions to develop more effective and rapid testing solutions. As the need for faster, more accurate antimicrobial susceptibility testing grows, market players are focusing on expanding their product portfolios and improving the integration of advanced technologies like artificial intelligence and machine learning to enhance diagnostic capabilities.

Recent Developments:

• BioMerieux launched the VITEK MS, a new solution for rapid antimicrobial susceptibility testing in clinical diagnostics, improving patient outcomes.
• Thermo Fisher completed the acquisition of Patheon, enhancing its capabilities in molecular diagnostics and antimicrobial resistance testing.
• Abbott's ID NOW diagnostic platform received FDA approval for rapid detection of antimicrobial resistance (AMR) in clinical samples.
• Cepheid launched the GeneXpert Omni, offering next-gen PCR technology that provides rapid antimicrobial susceptibility testing in resource-limited settings.
• Danaher acquired Bio-Rad's microbial testing division, expanding its antimicrobial resistance testing offerings with enhanced diagnostic tools.

List of Leading Companies:

• BioMerieux
• Thermo Fisher Scientific
• Becton Dickinson and Company (BD)
• Abbott Laboratories
• Danaher Corporation
• VITEK 2 (BioMerieux)
• Roche Diagnostics
• Cepheid
• HUMAN Diagnostics
• Liofilchem
• Himedia Laboratories
• Merck & Co.
• Biomérieux
• Corning Inc.
• Quidel Corporation

Report Scope: